MDT — Medtronic plc.

Is MDT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Overbought As of August 19, 2026

Medtronic plc. (MDT) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $92.09. The rating moved from Neutral to Overbought on August 7, 2026.

See all overbought Healthcare stocks →

AI analysis

Medtronic is positioned on a stable foundation of diversified device franchises, strong installed bases, and recurring aftermarket revenue that support steady cash generation. Near-term upside is supported by procedural volume normalization, selective product cycle catalysts, and supportive equity market flows; however, reimbursement dynamics, regulatory/recall risks, and hospital capital constraints remain key watch items. Performance over the next month will hinge on procedure trends, execution on innovation and margin initiatives, and any macro or data-driven shifts in investor risk appetite.

Key factors

  • Large, diversified medtech franchise with strong installed base across cardiovascular, neurological, diabetes and surgical portfolios supporting stable recurring revenue and service/consumables sales
  • Solid financial profile with consistent cash flow generation, dividend history, and capacity for share buybacks and targeted M&A to augment growth
  • Product pipeline and innovation in minimally invasive surgery, neuromodulation, and diabetes care that can drive medium-term organic growth and pricing power in key markets
  • Aftermarket and service revenue characteristics provide revenue stability that cushions near-term cyclical weakness
  • Favorable thematic tailwinds in biologics and diagnostics that indirectly support device demand (hospital investment, procedural volumes) and potential OEM supply relationships
  • Current market tone (mild risk-on, earnings-driven flows) supports near-term upside, with institutional flows into equities rather than defensive assets

Risks

  • Reimbursement pressure and payer-driven margin compression from ongoing payer strategic rationalization and cost-containment initiatives
  • Regulatory risk and product recalls that can materially affect sales and margins in device businesses
  • Intense competition from other large medtech and specialty device firms, including device commoditization in some segments
  • Macroeconomic or hospital budget constraints that depress capital spending and elective procedure volumes
  • Foreign exchange exposure given broad international footprint
  • Execution risk on new product launches and integration risk from acquisitions
  • Geopolitical tensions or supply-chain disruptions that could affect manufacturing or distribution

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for MDT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.